Blood Profiling Atlas
Seven Bridges announced that its biomedical data analysis platform will be used by the Cancer Moonshot’s Blood Profiling Atlas project. The project is designed to accelerate the development and approval of simple, accurate, and reliable blood tests for cancer diagnosis and precision treatment.
To support this work, Seven Bridges is collaborating with the National Cancer Institute and the Food and Drug Administration, in addition to AstraZeneca, Celgene, Eli Lilly and Company, Epic Sciences/Memorial Sloan Kettering Cancer Center, Foundation Medicine, Genentech, Guardant Health, Novartis, Personal Genome Diagnostics, Pfizer, Sage Bionetworks, ThermoFisher, University of Chicago, University of Michigan and the University of Southern California.
Seven Bridges Accelerates Biopharmaceutical R&D Innovation
We work with leading biopharmaceutical companies and governments to deliver a platform that harnesses the full power of genomic, transcriptomic, epigenomic, and proteomic data to identify biological targets and stratify patients in clinical trials.
Partners choose to work with us because we repeatedly show Seven Bridges to be the fastest, most effective way to create a multi-omic analysis layer across a global organization. Our clients dramatically increase the pace at which they discover, develop and deliver therapies for precision medicine.
The big-data opportunity in pharmaceutical R&D is real, and the rewards will be great for companies that succeed.
HOW BIG DATA CAN REVOLUTIONIZE PHARMACEUTICAL R&D —McKinsey&Company
Our Platform drives drug discovery and development
The Seven Bridges Platform supports research and development projects at all stages, across diverse therapeutic areas. Clients use Seven Bridges to integrate and analyze their molecular and clinical data assets in order to find and validate targets, discover clinical biomarkers and design personalized therapeutics.
By enabling deep molecular characterization of clinical cohorts, Seven Bridges also supports sophisticated trial stratification and rapid decision. In addition, we use the Platform to develop and deploy advanced bioinformatic workflows for our clients that help them do initial research and then use it to scale delivery into the clinic.